d-streptamine,o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1.fwdarw.2)-o
Dihydrostreptomycin sulfate
CAS: 5490-27-7
Molecular Formula: C21H43N7O16S
d-streptamine,o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1.fwdarw.2)-o - Names and Identifiers
d-streptamine,o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1.fwdarw.2)-o - Physico-chemical Properties
| Molecular Formula | C21H43N7O16S |
| Molar Mass | 681.67 |
| Specific Rotation(α) | D25 -88.5° (1% soln) |
| Water Solubility | Soluble in water |
| Solubility | H2O: 50mg/mL, clear, faintly yellow |
| Appearance | crystalline |
| Color | white to light yellow |
| Merck | 13,3201 |
| BRN | 3894221 |
| Storage Condition | Inert atmosphere,2-8°C |
| In vitro study | The main mechanism by which Dihydrostreptomycin exerts its antibacterial effects is to bind bacterial riboproteosomes and modify their functions, resulting in reduced and abnormal protein translation. It transports Kappa and glutamate out of the cell and dihydrostreptomycin into the cell by binding to a specific site of MscL and changing its conformation to enter the bacterial cell. |
| In vivo study | Dihydrostreptomycin sulfate causes inner ear injury in a mouse model, and after Dihydrostreptomycin sulfate-induced injury, a cell proliferation effect may occur in the spiral ligament. This may be related to the repair of cochlear function. |
d-streptamine,o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1.fwdarw.2)-o - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | 22 - Harmful if swallowed |
| Safety Description | 24/25 - Avoid contact with skin and eyes. |
| WGK Germany | 3 |
| RTECS | WK2236000 |
| TSCA | Yes |
| HS Code | 29412030 |
d-streptamine,o-2-deoxy-2-(methylamino)-alpha-l-glucopyranosyl-(1.fwdarw.2)-o - References
| EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
| Application | Dihydrostreptomycin (stored in the form of dihydrostreptomycin sulfate) is a highly effective β-lactam antibiotic, it has the advantages of strong bactericidal activity, low toxicity, wide indications and good clinical efficacy, and is suitable for infectious diseases caused by a variety of gram negative bacteria, such as tuberculosis, pertussis, plague, etc, currently, it is widely used in veterinary clinical trials. |
| preparation | a. Oxalic acid is added to the streptomycin fermentation broth at a ratio of 6kg/m3, then the pH is adjusted to 2.5 with sulfuric acid, heated to 60 °c, and then insoluble matter is removed by centrifugation or filtration, the pH was then adjusted to 7.0 with sodium hydroxide to prepare a stock solution of streptomycin; B. The streptomycin stock solution was saturated with sodium Type 110 resin, washed with soft water and press dry, and then eluted with 5.0 dilute sulfuric acid to obtain streptomycin sulfate eluent; c. The streptomycin elution solution was saturated with macroporous primary amine resin D303 or D318, then washed with purified water, and then analyzed by 8.0 dilute sulfuric acid cycle to prepare streptomycin sulfate solution; d. The streptomycin sulfate solution with sodium hydroxide to adjust the pH to 6.5, according to the ratio of 5.0g/billion units to add reducing agent potassium borohydride, before adding the reducing agent, it is dissolved in 0.05 sodium hydroxide solution according to the mass volume ratio of 10%, and then adjusted to pH 7.0 with sulfuric acid to prepare streptomycin sulfate hydrogenation solution; e. The hydrogenation solution of streptomycin sulfate was saturated with sodium type D152 resin, and then washed with no brine, and then eluted with 5.5 dilute sulfuric acid to obtain dihydrostreptomycin sulfate eluent; f. The purified liquid of dihydrostreptomycin sulfate was prepared by passing the eluent of dihydrostreptomycin sulfate into two ion exchange resins of hydrogen mixed bed in series; the mixed bed ion exchange resin consists of 1 × 25 resin and 703 resin in a volume ratio of 1: 0.3 mixed composition; g. After adjusting the pH of the purified liquid of dihydrostreptomycin sulfate to 4.0 with calcium hydroxide, adding 0.5 mass-to-volume active carbon, and the filtrate obtained after filtration is the filtered liquid of dihydrostreptomycin sulfate; h. The dihydrostreptomycin sulfate concentrated solution was prepared by concentrating the filtered solution with a molecular weight cut-off of 150D nanofiltration membrane; I. Add 1.0 (mass/volume) active carbon to the concentrated dihydrostreptomycin sulfate solution, and the filtrate obtained after filtration is the concentrated dihydrostreptomycin sulfate solution; j. The dihydrostreptomycin sulfate decolorization concentrate was filtered with a hollow fiber ultrafiltration membrane with a molecular weight cut-off of 4000D to prepare the final product of dihydrostreptomycin sulfate concentrate. k. The dihydrostreptomycin sulfate finished product concentrate was spray-dried with a two-flow airflow atomizer to prepare the dihydrostreptomycin sulfate finished powder. |
| biological activity | dihydroxysulfate is an aminoglycoside antibiotic used to treat bacterial diseases in cattle, pigs and sheep. Dihydrostreptomycin is a derivative of streptomycin. |
| Target | Value |
Last Update：2024-04-09 02:00:23
Supplier List
Multiple Specifications
Product Name: Dihydrostreptomycin sesquisulfate Visit Supplier Webpage Request for quotationCAS: 5490-27-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Multiple Specifications
Product Name: Dihydrostreptomycin sesquisulfate Visit Supplier Webpage Request for quotationCAS: 5490-27-7
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History